Hidroferol (Calcifediol Monohydrate)

Hidroferol is used to address conditions related to inadequate vitamin D status.

• Treatment of vitamin D deficiency in adults.
• Management of secondary hyperparathyroidism, particularly in chronic kidney disease.
• Support of bone mineralization in individuals at risk of osteomalacia.
• Adjunct to calcium supplementation for maintaining normal serum calcium and phosphate concentrations.
• Prevention of hypocalcemia in patients receiving long‑term glucocorticoid therapy.

• Calcifediol monohydrate is the 25‑hydroxy form of vitamin D3; after oral absorption it circulates as 25‑hydroxyvitamin D, the major storage form. Hepatic 25‑hydroxylase converts vitamin D3 to calcifediol, bypassing this step and allowing a rapid increase in serum 25‑hydroxyvitamin D. The elevated metabolite binds to the vitamin D receptor (VDR) in target tissues, promoting transcription of genes that enhance intestinal calcium and phosphate absorption and modulate parathyroid hormone secretion.

Adverse reactions to Hidroferol are generally related to excessive vitamin D activity.

Common

• Mild hypercalcemia (elevated serum calcium)
• Nausea or vomiting
• Constipation or abdominal discomfort
• Headache
• Fatigue

Serious

• Severe hypercalcemia with cardiac arrhythmia
• Nephrolithiasis or renal impairment
• Hypercalciuria leading to kidney stones
• Allergic reactions such as rash or angioedema
• Hyperphosphatemia in susceptible individuals

Before using Hidroferol, consider the following precautions.

• Assess baseline serum calcium, phosphate, and 25‑hydroxyvitamin D levels.
• Use cautiously in patients with a history of hypercalcemia, kidney stones, or renal disease.
• Monitor for signs of hypercalcemia, especially when combined with calcium or vitamin D supplements.
• Avoid use in individuals with known hypersensitivity to calcifediol or excipients.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Adjust dosage in patients with malabsorption syndromes or liver impairment.

Hidroferol may interact with several medications.

Avoid

• High‑dose calcium supplements or vitamin D preparations that could cause hypercalcemia.
• Thiazide diuretics, which reduce urinary calcium excretion and increase hypercalcemia risk.
• Certain antacids containing calcium or magnesium that may affect absorption.

Use with caution

• Corticosteroids, which can alter vitamin D metabolism.
• Anticonvulsants (e.g., phenobarbital, phenytoin) that increase vitamin D catabolism.
• Bisphosphonates, as altered calcium levels may affect their efficacy.
• Loop diuretics, which increase calcium excretion and may require monitoring.